BrainsGate is a medical device company that specializes in a novel treatment modality known as electrical SPG (sphenopalatine ganglion) stimulation. This innovative platform technology is designed to enhance cerebral blood flow, which has significant implications for treating various central nervous system disorders. The company is particularly focused on improving outcomes for patients who have experienced ischemic strokes, aiming to deliver treatment within a critical 24-hour window following the onset of symptoms. This approach addresses a pressing medical need, as ischemic stroke is a leading cause of long-term disability and mortality among adults.

In addition to its focus on ischemic stroke, BrainsGate is also exploring the potential of its technology for treating vascular dementia. The company’s commitment to advancing clinical research is underscored by ongoing studies, including the ImpACT24 trial, which has received positive evaluations from the Data Safety Monitoring Board. By leveraging electrical SPG stimulation, BrainsGate aims to provide new hope for patients suffering from these debilitating conditions, highlighting the transformative potential of their technology in the field of neurology.

Israel

BrainsGate is a medical device company committed to developing innovative therapies for patients suffering from Central Nervous System (CNS) diseases. The company's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow.

BrainsGate is exploring several applications for its technology, and is currently focusing on two directions: treatment of acute ischemic stroke, and chronic SPG stimulation to treat vascular dementia patients.

Brainsgate

Company Details